川北医学院学报2017，Vol.32Issue(1)：57-59,63,4.DOI:10.3969/j.issn.1005-3697.2017.01.016
雷替曲塞联合奥沙利铂治疗中晚期原发性肝癌的临床研究
Clinical study of raltitrexed combined with oxaliplatin in the treatment of middle and advanced primary liver cancer
摘要
Abstract
Objective:To explore the clinical efficacy and drug-toxic reactions of raltitrexed combined with oxaliplatin (RALOX) in the treatment of middle and advanced primary liver cancer (PLC).Methods:A total of 34 patients with middle and advanced PLC were selected as the observation group and treated with RALOX protocol,and another 36 patients with middle and advanced PLC in corresponding period and treated with symptomatic support treatment were took as the control group.Objective remission rate (OR),disease-control rate (DCR),median survival rate (mOS),median progression-free survival (mPFS),1-year survival rate (SR) as well as toxic and adverse reactions were evaluated every 2 cycle.Results:The observation group was notably better than the control group in OR,DCR,mOS and mPFS (P ＜ 0.05).The chemotherapy-induced toxic and adverse reactions were mainly mild and moderate gastrointestinal reactions,renal toxicity,liver toxicity,myelosuppression and peripheral nervous toxicity,which were relieved after positive treatment.Conclusions:RALOX protocol is safe and effective in the treatment of middle and advanced PLC,has excellent disease control and survival benefits,and is tolerable in toxic and adverse reactions,thus deserving to be widely applied in clinic.关键词
原发性肝癌/奥沙利铂/雷替曲塞/化疗Key words
Primary liver cancer/Oxaliplatin/Raltitrexed/Chemotherapy分类
医药卫生引用本文复制引用
沈永奇,黄军,陈超庭,斯韬,王志祥,谢华东,孔祥应,刘金娥,韩朝稳..雷替曲塞联合奥沙利铂治疗中晚期原发性肝癌的临床研究[J].川北医学院学报,2017,32(1):57-59,63,4.基金项目
广西卫计委科研项目(Z2014408) （Z2014408）
柳州市科技攻关项目(2014J030424) （2014J030424）
